Baloxavir Marboxil
FDA-approved product (tablet, oral), marketed as Baloxavir Marboxil, Xofluza.
- Registered studies
- 24
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Influenza
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antivirals
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX25
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
24registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Baloxavir Marboxil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
NCT04141930 · start 2019-11-01
Registered record
- Registry ID
- NCT04141930
- Conditions
- Influenza; Respiratory Viral Infection
- Interventions
- Baloxavir Marboxil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2019-11-01
- Completion
- 2020-04-01
- Enrolment
- 481
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenza; Respiratory Viral InfectionInterventionBaloxavir MarboxilPhasePhase 4Registry statusCompletedStudy to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
NCT03969212 · start 2019-10-10
Registered record
- Registry ID
- NCT03969212
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-10-10
- Completion
- 2024-05-10
- Enrolment
- 4,138
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir Marboxil; PlaceboPhasePhase 3Registry statusCompletedStudy to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants
NCT03959332 · start 2019-06-19
Registered record
- Registry ID
- NCT03959332
- Conditions
- Healthy Volunteer
- Interventions
- Baloxavir Marboxil
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2019-06-19
- Completion
- 2019-07-11
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteerInterventionBaloxavir MarboxilPhaseNot applicableRegistry statusCompletedStudy to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
NCT03653364 · start 2019-01-23
Registered record
- Registry ID
- NCT03653364
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-01-23
- Completion
- 2023-04-03
- Enrolment
- 49
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir MarboxilPhasePhase 3Registry statusCompletedStudy to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
NCT03684044 · start 2019-01-08
Registered record
- Registry ID
- NCT03684044
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-01-08
- Completion
- 2020-03-16
- Enrolment
- 363
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir Marboxil; PlaceboPhasePhase 3Registry statusCompletedStudy to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
NCT03629184 · start 2018-11-20
Registered record
- Registry ID
- NCT03629184
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil; Oseltamivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2018-11-20
- Completion
- 2019-04-03
- Enrolment
- 173
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir Marboxil; OseltamivirPhasePhase 3Registry statusCompletedStudy of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
NCT02949011 · start 2017-01-11
Registered record
- Registry ID
- NCT02949011
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil; Placebo to Baloxavir Marboxil; Oseltamivir; Placebo to Oseltamivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-01-11
- Completion
- 2018-04-20
- Enrolment
- 2,184
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir Marboxil; Placebo to Baloxavir Marboxil; Oseltamivir; Placebo to OseltamivirPhasePhase 3Registry statusCompletedA Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
NCT02954354 · start 2016-12-08
Registered record
- Registry ID
- NCT02954354
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil; Placebo to Baloxavir Marboxil; Oseltamivir; Placebo to Oseltamivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-12-08
- Completion
- 2017-04-24
- Enrolment
- 1,436
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfluenzaInterventionBaloxavir Marboxil; Placebo to Baloxavir Marboxil; Oseltamivir; Placebo to OseltamivirPhasePhase 3Registry statusCompletedRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707 · start 2016-04-11
Registered record
- Registry ID
- NCT02735707
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline; Amoxicillin-clavulanate; Standard course macrolide; Extended course macrolide; No systemic corticosteroid; Fixed-duration Hydrocortisone; Shock-dependent hydrocortisone; Fixed-duration higher dose Hydrocortisone; No antiviral agent for influenza; Five-days oseltamivir; Ten-days oseltamivir; No antiviral agent for COVID-19; Lopinavir / Ritonavir; Hydroxychloroquine; Hydroxychloroquine + lopinavir/ritonavir; Ivermectin; No immune modulation for COVID-19; Interferon beta-1a; Anakinra; Tocilizumab; Sarilumab; Local standard venous thromboprophylaxis; Therapeutic dose anticoagulation; Conventional low dose thromboprophylaxis; Intermediate dose thromboprophylaxis; Continuation of therapeutic dose anticoagulation; No immunoglobulin; Convalescent plasma; Delayed administration of convalescent plasma; No vitamin C; Vitamin C; No antiplatelet; Aspirin; P2Y12 inhibitor; No simvastatin; Simvastatin; Eritoran; Apremila
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2016-04-11
- Completion
- 2028-02
- Enrolment
- 20,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCommunity-acquired Pneumonia, Influenza, COVID-19InterventionCeftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline +37 morePhasePhase 3Registry statusRecruiting